BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Cancer cell, dropper, test tubes
Newco news

Mosaic collects $28M to find cancer targets and biomarkers

April 10, 2023
By Nuala Moran
No Comments
Two years after its formation, Mosaic Therapeutics Ltd. has raised $28 million in a series A to begin commercialization of research carried out by the Translational Cancer Genomics Lab at the Sanger Institute in Cambridge, U.K., into the genetic vulnerabilities of multiple tumor types and how that impacts response to therapy.
Read More
T cells
Newco news

Thymus-focused T-cell therapy platform draws EU funding to startup Smart Immune

March 31, 2023
By Nuala Moran
No Comments
Smart Immune SAS has received €17.5 million (US$19 million) in grant and equity funding from an EU innovation program to advance development of its “thymus in a dish” T-cell therapy.
Read More
Digestive system
Newco news

Alternative, antagonist approach to GI diseases unveiled by ThirtyFiveBio

March 30, 2023
By Caroline Richards
No Comments
The role of G protein-coupled receptor 35 (GPR35) in gastrointestinal (GI) diseases has been genetically validated for some time, with several pharmaceutical companies advancing programs designed to tackle the target; however, most of these efforts to date have focused on increasing GPR35 activity. ThirtyFiveBio’s approach is different: The newly founded virtual biotech company believes that antagonizing the target and thereby blocking unwanted GPR35 signaling may be a more appropriate way to address GI conditions, including digestive tract cancers.
Read More
CDK2 with cyclin E
Newco news

Former G1 trio leading charge on CDK2 inhibitor in resistant cancer at Incyclix

March 29, 2023
By Jennifer Boggs
No Comments
More than a decade ago, three scientists were part of a team at G1 Therapeutics Inc. that led to the now-approved CDK4/6 inhibitor Cosela (trilaciclib). The same work also led to findings showing CDK2 as a promising target for cancers that developed resistance to CDK4/6 inhibition.
Read More
Lab research with pipette, microsope

Orakl developing in vitro diagnostic test using organoids for colorectal cancer

March 28, 2023
By Bernard Banga
No Comments
The Gustave Roussy cancer center, specializing in cancer treatment, and its technology transfer subsidiary Gustave Roussy Transfert, reported the creation of startup Orakl SA, which develops a technology for modeling cancer tumors called the patient tumor avatar. Orakl leverages a unique collection of patient tumor avatars, combining biological and clinical data to fuel the therapeutic arsenal to fight cancer.
Read More
Elderly woman holding illustration of brain with missing puzzle piece
Newco news

‘Not a slowdown, a reversal’: Truebinding tackling Alzheimer’s via galectin-3

March 17, 2023
By Jennifer Boggs
No Comments
In Alzheimer’s, the amyloid beta hypothesis has proved most persistent in terms of drug development efforts to date, but aggregation of other pathogenic factors – phosphorylated tau (p-tau), APOE4, TREM2 and alpha-synuclein, for example – have also emerged as hallmarks of the disease. It’s that aggregation that seven-year-old Truebinding Inc. aims to target with its lead program, TB-006, a monoclonal antibody against galectin-3.
Read More
Gold wireframe handshake
Newco news

A $4 million handshake with investor helps propel First Wave Biopharma’s CF offering

March 16, 2023
By Caroline Richards
No Comments
An investor has seen promise in First Wave Biopharma Inc.’s targeted, systemic gastrointestinal disease biotherapeutics, offering $4 million in a private placement as enrollment picks up pace in a phase II trial for the company’s lead candidate, adrulipase.
Read More
White Euro symbol on blue background
Newco news

Teitur Trophics targeting neurodegenerative disease with €28M series A round

March 14, 2023
By Nuala Moran
No Comments
Newco Teitur Trophics ApS has raised €28 million (US$30.1 million) in a series A with which it will lay out a new route to targeting sortilin in the treatment of neurodegenerative diseases. The company is targeting the sortilin-related Vps10p domain containing receptor, which plays a role in regulating a number of pathways involved in the control of neuronal viability and function.
Read More
Concept art for RNA interference, gene silencing.
Neurology/Psychiatric

Switch Therapeutics launches with focus on conditionally activated siRNA molecules

March 14, 2023
No Comments
Switch Therapeutics Inc. has announced its launch following US$52 million of financing. The company was founded on the premise of a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science.
Read More
Targets with arrows
Newco news

Flagship puts $50M toward targeted tissue-homing tech startup

March 10, 2023
By Caroline Richards
No Comments
In an ideal world, when a patient takes a medicine, it acts only at the specific site of disease in the human body whilst sparing healthy tissues. But it almost goes without saying that with many drug regimens, side effects or complications are part of the package. Working behind the scenes to address this limitation over the past couple of years, Cambridge, Mass.-based venture capital company Flagship Pioneering is now publicizing its platform of “programmable medicines” that directly and precisely target diseased tissue, funnelling $50 million of investment in the technology and recognising its achievements formally through the launch of Ampersand Biomedicines.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 43 44 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing